Semaglutide 2.4 mg in Patients With Poor Weight-loss

NCT05073835 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether semaglutide 2.4 mg helps people with obesity, diabetes, or metabolic syndrome lose weight.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 70 people

Who can join Ages 18–65 · all sexes

Timeline Started 2022-11 · est. completion 2025-09

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT05073835 ↗

Description as written by the study sponsor.

A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery. The primary aim of this trial is to determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients with poor weight loss following gastric bypass or sleeve gastrectomy.

Treatments tested

Semaglutide 3 mg Drug

Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
Placebo Drug

Placebo

Main thing measured	Weight loss
Sponsor	University College, London
Conditions studied	Obesity, Diabetes, Metabolic Syndrome
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05073835 ↗